Showing results (101-110 of 125) with videos related to

Sort By:
Pageof 13
Breast Cancer Research : BCR|November 3, 2020
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancerAna C Garrido-Castro, Cristina Saura, Romualdo Barroso-Sousa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2024
A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 StudyPatrick Neven, Nicole Stahl, Maria Vidal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2025
Palbociclib, trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer: randomised phase II, SOLTI-1303 PATRICIA trialEva Ciruelos, Tomás Pascual, Guillermo Villacampa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2016
Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function TrialKarin Ribi, Weixiu Luo, Jürg Bernhard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2020
Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA TrialEva Ciruelos, Patricia Villagrasa, Tomás Pascual, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2026
Pembrolizumab and Paclitaxel in HR+/HER2- Breast Cancer with HER2-Enriched or Basal-Like SubtypesBenedetta Conte, Fara Brasó-Maristany, Tomás Pascual, et al.
The Lancet. Oncology|August 13, 2019
Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialCristina Saura, Dominik Hlauschek, Mafalda Oliveira, et al.
European Journal of Cancer (Oxford, England : 1990)|January 8, 2025
Efficacy outcomes of CDK4/6 inhibitors in combination with endocrine therapy treatment in hormone receptor-positive/HER2-negative advanced breast cancer according to PAM50 intrinsic subtype: Primary results of SOLTI-1801 CDK-PREDICT studyPablo Tolosa, Tomás Pascual, Olga Martínez-Saez, et al.
Breast Cancer Research and Treatment|February 28, 2026
Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT studyPablo Tolosa, Isabel García-Fructuoso, Tomás Pascual, et al.
The Lancet. Oncology|December 16, 2019
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trialAleix Prat, Cristina Saura, Tomás Pascual, et al.
Pageof 13